BlackBerry Ltd (NASDAQ:BBRY),’s Q10 is now available in white and goldversions at ShopBlackBerry UK for customers who wanted to own one but wished its look to be more luxurious and pricey. The Q10 model from BlackBerry is much similar in design to the BlackBerry 7 models. BlackBerry Ltd (NASDAQ:BBRY), shares after opening at $7.68 moved to $7.99 on last trade day and at the end of the day closed at $7.97. Company price to sales ratio in past twelve months was calculated as 0.33 and price to cash ratio as 1.53. BlackBerry Ltd (NASDAQ:BBRY), showed a positive weekly performance of 8.58%.
InvenSense Inc (NYSE:INVN), on its FQ4 CC for FQ1 revenue of $63M-$66M and EPS of $0.07-$0.08, below a consensus of $69.1M and $0.16. Top customer Samsung is expected to continue accounting for a mid-30s % of sales. InvenSense Inc (NYSE:INVN), shares fell 4.37% in last trading session and ended the day on $20.59. InvenSense Inc (NYSE:INVN), return on equity ratio is recorded as 9.00% and its return on assets is 7.20%. InvenSense Inc (NYSE:INVN), yearly performance is 125.77%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s stock jumped 3.11% to $6.60. The company on Apr. 14 reported that Eisai Inc. has launched a national television advertising campaign for BELVIQ (lorcaserin HCl), an FDA-approved prescription treatment for chronic weight management. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), shares moved up 4.06% in last trading session and was closed at $6.66, while trading in range of $ 6.25 – 6.72. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), year to date (YTD) performance is 13.85%.
AstraZeneca plc (ADR) (NYSE:AZN), rejected Pfizer Inc.’s sweetened takeover proposal, saying the 63.1 billion-pound ($106.5 billion) offer fails to recognize the value of the promising experimental medicines under development by the U.K.’s second-biggest drugmaker. AstraZeneca plc (ADR) (NYSE:AZN), weekly performance is 17.50%. On last trading day company shares ended up $81.09. AstraZeneca plc (ADR) (NYSE:AZN), distance from 50-day simple moving average (SMA50) is 21.92%. Analysts mean target Price for the company is $70.05.
Leave a Reply